John M. Bedtelyon

Array ( [id] => 12751273 [patent_doc_number] => 20180142258 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-24 [patent_title] => METHODS AND COMPOSITIONS FOR THE ACTIVATION OF GAMMA-DELTA T-CELLS [patent_app_type] => utility [patent_app_number] => 15/850937 [patent_app_country] => US [patent_app_date] => 2017-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21636 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 182 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15850937 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12751270 [patent_doc_number] => 20180142257 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-24 [patent_title] => METHODS AND COMPOSITIONS FOR THE ACTIVATION OF GAMMA-DELTA T-CELLS [patent_app_type] => utility [patent_app_number] => 15/849062 [patent_app_country] => US [patent_app_date] => 2017-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21428 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15849062 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16695538 [patent_doc_number] => 10946107 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-16 [patent_title] => Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, HAO1) and methods of use thereof [patent_app_type] => utility [patent_app_number] => 15/841486 [patent_app_country] => US [patent_app_date] => 2017-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 48542 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15841486 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16305552 [patent_doc_number] => 10774331 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-15 [patent_title] => Methods of inducing insulin production [patent_app_type] => utility [patent_app_number] => 15/837377 [patent_app_country] => US [patent_app_date] => 2017-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 27959 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15837377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15800809 [patent_doc_number] => 20200123547 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-23 [patent_title] => NUCLEIC ACID-BASED ASSEMBLY AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/467151 [patent_app_country] => US [patent_app_date] => 2017-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27074 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16467151 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16277060 [patent_doc_number] => 10760077 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-01 [patent_title] => Selective reduction of the deleterious activity of extended tri-nucleotide repeat containing genes [patent_app_type] => utility [patent_app_number] => 15/833891 [patent_app_country] => US [patent_app_date] => 2017-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 43 [patent_no_of_words] => 18549 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15833891 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15114461 [patent_doc_number] => 20190343863 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-14 [patent_title] => MODULATION OF LNC05 EXPRESSION [patent_app_type] => utility [patent_app_number] => 16/465083 [patent_app_country] => US [patent_app_date] => 2017-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20582 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16465083 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13479667 [patent_doc_number] => 20180291376 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-11 [patent_title] => COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING [patent_app_type] => utility [patent_app_number] => 15/818073 [patent_app_country] => US [patent_app_date] => 2017-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12840 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15818073 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16664932 [patent_doc_number] => 10934162 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-02 [patent_title] => MicroRNA initiated DNAzyme motor operating in living cells [patent_app_type] => utility [patent_app_number] => 15/814206 [patent_app_country] => US [patent_app_date] => 2017-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 35 [patent_no_of_words] => 21687 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 247 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15814206 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15071431 [patent_doc_number] => 10465192 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-05 [patent_title] => Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1 [patent_app_type] => utility [patent_app_number] => 15/804445 [patent_app_country] => US [patent_app_date] => 2017-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 5 [patent_no_of_words] => 25185 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15804445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12729655 [patent_doc_number] => 20180135052 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-17 [patent_title] => APTAMERS AGAINST GLIOMA CELLS [patent_app_type] => utility [patent_app_number] => 15/801928 [patent_app_country] => US [patent_app_date] => 2017-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6184 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15801928 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16606170 [patent_doc_number] => 10907165 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-02 [patent_title] => Methods of enhancing translation ability and stability of RNA molecules, treatments, and kits [patent_app_type] => utility [patent_app_number] => 16/345786 [patent_app_country] => US [patent_app_date] => 2017-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 23538 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16345786 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16061439 [patent_doc_number] => 10689654 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-23 [patent_title] => Bivalent siRNA chimeras and methods of use thereof [patent_app_type] => utility [patent_app_number] => 15/726851 [patent_app_country] => US [patent_app_date] => 2017-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 32 [patent_no_of_words] => 16415 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15726851 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13026817 [patent_doc_number] => 10036025 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-31 [patent_title] => Oligonucleotide compositions with enhanced efficiency [patent_app_type] => utility [patent_app_number] => 15/724224 [patent_app_country] => US [patent_app_date] => 2017-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 22278 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15724224 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12770662 [patent_doc_number] => 20180148722 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-31 [patent_title] => Dual Targeting siRNA Agents [patent_app_type] => utility [patent_app_number] => 15/724175 [patent_app_country] => US [patent_app_date] => 2017-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44456 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15724175 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12178953 [patent_doc_number] => 20180037890 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-08 [patent_title] => 'OLIGONUCLEOTIDE COMPOSITIONS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/714671 [patent_app_country] => US [patent_app_date] => 2017-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 24391 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15714671 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16663859 [patent_doc_number] => 10933081 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-02 [patent_title] => Myostatin iRNA compositions and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/335125 [patent_app_country] => US [patent_app_date] => 2017-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 11 [patent_no_of_words] => 13189 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16335125 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14069535 [patent_doc_number] => 20190083655 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-21 [patent_title] => VIVO RNA OR PROTEIN EXPRESSION USING DOUBLE-STRANDED CONCATEMERIC DNA INCLUDING PHOSPHOROTHIOATED NUCLEOTIDES [patent_app_type] => utility [patent_app_number] => 15/707074 [patent_app_country] => US [patent_app_date] => 2017-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9245 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15707074 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14978391 [patent_doc_number] => 10443101 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-15 [patent_title] => Exonic splicing enhancers and exonic splicing silencers [patent_app_type] => utility [patent_app_number] => 15/706485 [patent_app_country] => US [patent_app_date] => 2017-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 36 [patent_no_of_words] => 11655 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15706485 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12946240 [patent_doc_number] => 09834790 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2017-12-05 [patent_title] => Methods and compositions for the activation of gamma-delta T-cells [patent_app_type] => utility [patent_app_number] => 15/706481 [patent_app_country] => US [patent_app_date] => 2017-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 21366 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15706481 [rel_patent_id] =>[rel_patent_doc_number] =>)